Moxonidine shortage — AU supply status & alternatives

Moxonidine

—

🇦🇺 AUST R 300131

Limited supply · Australia

In declared shortage · 🇦🇺 Australia & also short in🇧🇪 BE

Limited supply

Reading today’s signals…

🇦🇺 AUAEMPA$4.00DPMQ A$22.84details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

Aug 2026

Sponsor est. via TGA

Product attributes reference data we hold

Active ingredient (INN)

Brand names	Gh

Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Marketing-authorisation holders	Southern Cross Pharma Pty Ltd, Mylan Health Pty Ltd, Lupin Australia Pty Limited, TEVA UK LIMITED +3 more

Registrations on file	26

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$4.00

AEMP

Dispensed (DPMQ)

A$22.84

incl. fees

Pack

moxonidine 200 microgram tablet, 30

Source: PBSEffective July 2026 · AUD

Other markets

🇬🇧 GB

£2.44

Drug Tariff

🇫🇷 FR

€3.83

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 6 resolved events

◷

1–7 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇧🇪

FAMHP · 4h ago

Medium

🇦🇺

Australia

TGA · 3h ago

Low

Verified timeline regulator events

🇦🇺 17 July 2026

low reported

🇧🇪 25 June 2026

medium reported

🇧🇪 17 June 2026

medium reported

🇦🇺 5 June 2026

low reported

🇦🇺 1 May 2026

low reported

🇧🇪 20 Apr 2026

medium reported

Sources official regulators

🇦🇺

TGA

verified 3h ago

verify ↗

🇧🇪

FAMHP

verified 4h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders26 registrations · 7 MA holders

Product	Strength	Form	Market	MA holder	Status
Gppl	200 microgram	—	🇦🇺 AU	—	Active
Scp	400 microgram	—	🇦🇺 AU	Southern Cross Pharma Pty Ltd	Active
Apo	200 microgram	—	🇦🇺 AU	Southern Cross Pharma Pty Ltd	Active
Scp	200 microgram	—	🇦🇺 AU	Southern Cross Pharma Pty Ltd	Active
Viatris	400 microgram	—	🇦🇺 AU	Mylan Health Pty Ltd	Active
Gx	200 microgram	—	🇦🇺 AU	Mylan Health Pty Ltd	Active
Gx	400 microgram	—	🇦🇺 AU	Mylan Health Pty Ltd	Active
Lapl	200 microgram	—	🇦🇺 AU	Lupin Australia Pty Limited	Active
Apo	400 microgram	—	🇦🇺 AU	Southern Cross Pharma Pty Ltd	Active
MOXONIDINE 300 MICROGRAM TABLETS	300 MICROGRAM	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
MOXONIDINE 400 MICROGRAM TABLETS	400 MICROGRAM	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
MOXONIDINE 0.2 MG FILM-COATED TABLETS	0.2 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
MOXONIDINE 0.3 MG FILM-COATED TABLETS	0.3 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
MOXONIDINE 0.4 MG FILM-COATED TABLETS	0.4 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
MOXONIDINE 200 MICROGRAM TABLETS	200 MICROGRAM	tablet	🇬🇧 GB	SANDOZ LIMITED	Active

+11 more registrations on file

Mederti Drug Report

Generated 1 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.